These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11395572)

  • 1. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin.
    Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG
    Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene.
    Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC
    Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial function, apoptosis and cell cycle delay in the WEHI-3B leukaemia cell line and its variant Ciprofloxacin-resistant WEHI-3B/CPX.
    Pessina A; Bonomi A; Casati S; Collotta A; Croera C; Marafante E; Palitti F; Gribaldo L
    Cell Prolif; 2007 Aug; 40(4):568-79. PubMed ID: 17635523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
    Danks MK; Schmidt CA; Cirtain MC; Suttle DP; Beck WT
    Biochemistry; 1988 Nov; 27(24):8861-9. PubMed ID: 2853972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
    Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
    Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
    Rappa G; Lorico A; Sartorelli AC
    Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S; Austin CA; Fisher LM
    Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
    Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
    Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
    Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
    Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
    De Isabella P; Capranico G; Binaschi M; Tinelli S; Zunino F
    Mol Pharmacol; 1990 Jan; 37(1):11-6. PubMed ID: 2153905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
    Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
    Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
    Rappa G; Lorico A; Sartorelli AC
    Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to Cholera Toxin (CT)-induced apoptosis.
    Pessina A; Croera C; Savalli N; Bonomi A; Cavicchini L; Turlizzi E; Guizzardi F; Guido L; Daprai L; Neri MG
    Cell Res; 2006 Mar; 16(3):306-12. PubMed ID: 16541129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.